Advertisement
RMD vs SOLV
Which Stock Would AI Choose? ResMed Inc. (RMD) vs. Solventum Corporation (SOLV) Stock Comparison
Key Takeaways
- Both RMD and SOLV operate in the healthcare sector, with RMD specializing in sleep and respiratory devices and SOLV offering a broader portfolio of health solutions.
- RMD has faced recent share price weakness around $220, despite projected EPS (earnings per share) growth of 17.7% for Q3 2026.
- SOLV trades near $69, with analysts maintaining a Moderate Buy rating and potential 26% upside.
- Year-to-date, both stocks have declined, with RMD down about 8-9% and SOLV down 9-18%.
- Tickeron's comparison indicates RMD as a stronger long-term buy relative to SOLV.
- Upcoming earnings for RMD (April 30, 2026) and SOLV (May 5, 2026) could influence near-term momentum.
Introduction
This stock comparison examines ResMed Inc. (RMD) and Solventum Corporation (SOLV), two healthcare-focused companies navigating current market dynamics. Both firms cater to growing demand in medical devices and solutions, making them relevant for investors seeking exposure to defensive sectors amid economic uncertainty. Traders monitoring relative performance may find value in their contrasting trajectories—RMD's established sleep apnea leadership versus SOLV's diversified post-spinoff portfolio. This analysis highlights recent market positioning, growth drivers, and sentiment shifts to aid informed decision-making in healthcare stock selection.
RMD Overview and Recent Performance
ResMed Inc. (RMD) is a global leader in digital health technologies and cloud-connected medical devices, primarily targeting sleep apnea, respiratory disorders, and out-of-hospital care. In recent market activity, the stock has experienced price weakness, trading around $220 after a year-to-date decline of approximately 8-9% and a past-month drop of about 3-4%. Sentiment has been influenced by broader sector pressures, though positive factors include a global sleep survey underscoring health priorities and strong EPS projections for upcoming quarters. Analysts anticipate 17.7% EPS growth to $2.79 for Q3 fiscal 2026, supporting long-term optimism despite short-term volatility.
SOLV Overview and Recent Performance
Solventum Corporation (SOLV), spun off from 3M in 2024, develops and commercializes healthcare solutions across wound care, health systems, and dental segments. Recent weeks have seen mixed performance, with shares around $69 following year-to-date losses of 9-18% and variable monthly gains or losses depending on volatility. Key influences include a Q4 2025 earnings beat with $1.57 EPS and ongoing share repurchases, tempered by market challenges. Analyst sentiment remains constructive with a Moderate Buy consensus and a price target implying 26% upside, ahead of Q1 fiscal 2026 results.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically 351 total bots that trade thousands of different tickers across various market conditions. Only 25 elite bots earn a spot in this section, selected for their suitability to current volatility and trends, featuring diverse styles like signal agents, virtual agents, and brokerage agents. These bots employ strategies across timeframes such as 60-minute, 15-minute, and 5-minute intervals, with filters for low, medium, and high volatility. Performance highlights include consistent pattern recognition and adaptive trading logic tailored to stocks like those in healthcare. Investors can explore these bots to enhance strategies; visit the page to review live stats and copy top performers.
Head-to-Head Comparison
RMD and SOLV share healthcare exposure but differ in business models: RMD's focused sleep and respiratory niche offers stability through recurring device demand, while SOLV's broader portfolio spans wound care and dental for diversified growth. Recent momentum shows both under pressure year-to-date, but RMD boasts a larger market cap (~$33B vs. ~$12B) and stronger EPS trajectory. Risk factors include sector headwinds like reimbursement changes for RMD and post-spinoff integration for SOLV. Market sentiment favors RMD's innovation catalysts, such as cloud-connected devices, over SOLV's acquisition pursuits, highlighting trade-offs in focus versus breadth.
Tickeron AI Verdict
Tickeron’s AI analysis currently favors RMD over SOLV for its superior long-term positioning, driven by consistent trend stability, robust EPS growth prospects, and established market leadership in a high-demand niche. While SOLV offers analyst upside potential, RMD edges out on relative momentum and lower volatility risks in recent activity.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RMD is a Hold and SOLV is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
RMD’s FA Score shows that 1 FA rating(s) are green whileSOLV’s FA Score has 1 green FA rating(s).
- RMD’s FA Score: 1 green, 4 red.
- SOLV’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
RMD’s TA Score shows that 5 TA indicator(s) are bullish while SOLV’s TA Score has 3 bullish TA indicator(s).
- RMD’s TA Score: 5 bullish, 3 bearish.
- SOLV’s TA Score: 3 bullish, 5 bearish.
Price Growth
RMD (@Pharmaceuticals: Other) experienced а -2.23% price change this week, while SOLV (@Pharmaceuticals: Other) price change was -4.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.83%. For the same industry, the average monthly price growth was -0.55%, and the average quarterly price growth was -14.44%.
Reported Earning Dates
RMD is expected to report earnings on Jul 30, 2026.
SOLV is expected to report earnings on Aug 06, 2026.
Industries' Descriptions
@Pharmaceuticals: Other (-1.83% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
| RMD | SOLV | RMD / SOLV | |
| Capitalization | 27.3B | 12.7B | 215% |
| EBITDA | 2.18B | 2.49B | 88% |
| Gain YTD | -21.348 | -7.168 | 298% |
| P/E Ratio | 18.17 | 9.00 | 202% |
| Revenue | 5.54B | 8.26B | 67% |
| Total Cash | 1.66B | 561M | 296% |
| Total Debt | 843M | 5.29B | 16% |
RMD | ||
|---|---|---|
OUTLOOK RATING 1..100 | 6 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 38 | |
PRICE GROWTH RATING 1..100 | 64 | |
P/E GROWTH RATING 1..100 | 85 | |
SEASONALITY SCORE 1..100 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| RMD | SOLV | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 62% | 2 days ago 50% |
| Stochastic ODDS (%) | 2 days ago 70% | 2 days ago 69% |
| Momentum ODDS (%) | 2 days ago 62% | 2 days ago 59% |
| MACD ODDS (%) | 2 days ago 59% | 2 days ago 50% |
| TrendWeek ODDS (%) | 2 days ago 60% | 2 days ago 60% |
| TrendMonth ODDS (%) | 2 days ago 59% | 2 days ago 67% |
| Advances ODDS (%) | 19 days ago 59% | 20 days ago 62% |
| Declines ODDS (%) | 13 days ago 59% | 8 days ago 59% |
| BollingerBands ODDS (%) | 2 days ago 72% | 2 days ago 56% |
| Aroon ODDS (%) | 2 days ago 61% | 2 days ago 81% |
Advertisement
RMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RMD has been loosely correlated with SOLV. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if RMD jumps, then SOLV could also see price increases.
| Ticker / NAME | Correlation To RMD | 1D Price Change % | ||
|---|---|---|---|---|
| RMD | 100% | -0.10% | ||
| SOLV - RMD | 46% Loosely correlated | -2.48% | ||
| COO - RMD | 46% Loosely correlated | -0.74% | ||
| BAX - RMD | 44% Loosely correlated | -1.16% | ||
| NVST - RMD | 41% Loosely correlated | -1.54% | ||
| RVTY - RMD | 40% Loosely correlated | -0.96% | ||
More | ||||
SOLV and
Correlation & Price change
A.I.dvisor indicates that over the last year, SOLV has been loosely correlated with RMD. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if SOLV jumps, then RMD could also see price increases.
| Ticker / NAME | Correlation To SOLV | 1D Price Change % | ||
|---|---|---|---|---|
| SOLV | 100% | -2.48% | ||
| RMD - SOLV | 46% Loosely correlated | -0.10% | ||
| BAX - SOLV | 45% Loosely correlated | -1.16% | ||
| NVST - SOLV | 44% Loosely correlated | -1.54% | ||
| ICUI - SOLV | 42% Loosely correlated | -3.01% | ||
| COO - SOLV | 42% Loosely correlated | -0.74% | ||
More | ||||